Richard Koya to Mice, Transgenic
This is a "connection" page, showing publications Richard Koya has written about Mice, Transgenic.
Connection Strength
0.261
-
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37.
Score: 0.074
-
Immune rejection in a humanized model of murine prostate cancer. Anticancer Res. 2010 Feb; 30(2):409-14.
Score: 0.063
-
WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer. 2021 02; 9(2).
Score: 0.034
-
Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res. 2018 05; 6(5):594-604.
Score: 0.028
-
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41.
Score: 0.023
-
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014 Jan 01; 74(1):153-161.
Score: 0.021
-
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFß) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med. 2012 Jun 19; 10:127.
Score: 0.019